The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Caris Life Sciences
Characterization of ERBB2 alterations in non-small cell lung cancer.
 
Vijendra Singh
Stock and Other Ownership Interests - Abbvie
 
Rebecca Feldman
No Relationships to Disclose
 
Ammar Sukari
Consulting or Advisory Role - Eisai; Merck
Research Funding - Eisai
 
Chul Kim
Consulting or Advisory Role - Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; Regeneron; Tesaro
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Tempus
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Gerold Bepler
No Relationships to Disclose
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Research Funding - Boehringer Ingelheim; Genentech/Roche; Ignyta; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Merck; Pfizer; Takeda
 
Luis E. Raez
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Sachin Gopalkrishna Pai
Consulting or Advisory Role - Caris Life Sciences
 
Chukwuemeka Ikpeazu
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - AstraZeneca; Eisai; Genentech/Roche; Merck
 
Ari M. Vanderwalde
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Genentech/Roche; Immunocore
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Polynoma (Inst); Replimune (Inst)
 
Joanne Xiu
Employment - Caris Life Sciences
 
Antoinette J. Wozniak
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Epic; Epizyme; HUYA Bioscience International; Karyopharm Therapeutics; KOL Connection; Lilly; Odonate Therapeutics; Premier, Inc.; WCCT Global
Research Funding - Boehringer Ingelheim
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Stephen V. Liu
Consulting or Advisory Role - Apollomics; ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Genentech; Guardant Health; HERON; Ignyta; Inivata; Janssen Oncology; Lilly; Loxo; Merck; MSD Oncology; Pfizer; PharmaMar; Regeneron; Roche; Taiho Pharmaceutical; Takeda; Tempus
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Esanex (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Molecular Partners (Inst); OncoMed (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca
Research Funding - Tempus